Condition
Recurrent Grade 3b Follicular Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Recurrent Grade 3b Follicular Lymphoma clinical trials that are recruiting, in United States. By phase: Phase 2 (3), Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest Recurrent Grade 3b Follicular Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma | Phase 2 | Scottsdale, Arizona and 6 other locations | Recruiting | Feb 19, 2025 |
| Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T | Phase 2 | Seattle, Washington | Recruiting | Jan 20, 2025 |
| Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma | Phase 1/2 | Minneapolis, Minnesota and 2 other locations | Recruiting | Aug 2, 2024 |
| Treatment for relapsed or refractory diffuse large B-cell lymphoma | Phase 2 | Duarte, California | Recruiting | Jan 5, 2023 |
| CAR-T therapy for HIV-related aggressive B-cell lymphoma | Phase 1 | Duarte, California and 6 other locations | Recruiting | Oct 14, 2021 |
All recruiting trials (5)
-
Using golcadomide and rituximab to prepare patients for CAR T-cell therapy in aggressive B-cell lymphoma
This study is testing if a combination of golcadomide and rituximab can help patients with aggressive B-cell lymphoma get ready for CAR T-cell therapy.
-
Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T
This trial tests whether giving odronextamab before CAR‑T cell therapy can keep disease under control in adults with relapsed or refractory large B‑cell lymphomas.
-
Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma
This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.
-
Treatment for relapsed or refractory diffuse large B-cell lymphoma
This study is testing a new combination of two treatments for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them respond better and live longer.
-
CAR-T therapy for HIV-related aggressive B-cell lymphoma
This study is testing a new CAR-T therapy to see if it can safely help people with HIV-related aggressive B-cell lymphoma that hasn't responded to other treatments.
Related topics
Quick answers
How many Recurrent Grade 3b Follicular Lymphoma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in United States. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.